Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement


Published in:
Archives of disease in childhood

DOI:
10.1136/adc.2010.199760

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement

Bart G P Koot, Olga H van der Baan-Slootweg, Christine L J Tamminga-Smeulders, Tammo H Pels Rijcken, Joke C Korevaar, Wim M van Aalderen, Peter L M Jansen, Marc A Benninga

ABSTRACT
Background Non-alcoholic fatty liver disease (NAFLD) has a high prevalence in obese children. Lifestyle intervention is the primary treatment for NAFLD. However, limited data are available regarding the efficacy of lifestyle interventions.

Objectives To prospectively determine the efficacy of a lifestyle intervention programme on NAFLD in severely obese children and identify the clinical parameters related to improvement in NAFLD.

Methods Children admitted to a lifestyle intervention programme were screened for NAFLD. Steatosis was defined as increased echogenicity of the liver on ultrasonography. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were used as surrogate markers for steatohepatitis. The lifestyle intervention programme consisted of physical exercise, dietary counselling and behavioural counselling for a period of 6 months.

Results 144 children were included with a mean age of 14.1 (±2.3) years, BMI z-score of 3.35 (±0.40) kg/m². Lifestyle intervention significantly reduced the prevalence of steatosis (31.2–11.9%, p<0.001) and the prevalence of elevated serum ALT (25.7–11.1%, p<0.001) and serum AST (13.3–4.3%, p<0.002). In multivariate regression analysis, improvement in the degree of steatosis and decrease in ALT and AST were all significantly related to improvement in insulin resistance. Improvement in insulin resistance only explained a small part of the observed changes in transaminases.

Conclusions A lifestyle intervention of 6 months is moderately effective in improving NAFLD in severely obese children. Improvement in insulin resistance is the clinical parameter most strongly associated with improvement in NAFLD. Other factors related to the successful treatment of NAFLD need to be identified so that these can be a focus for new lifestyle and drug interventions.

INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is well established as one of the complications of obesity. In severely obese children, NAFLD has a reported incidence ranging from 22% in a school-based population to 52% in those referred to obesity centres. The clinical spectrum of NAFLD consists of simple steatosis, steatohepatitis and cirrhosis. Important fibrosis and occasionally cirrhosis can occur at paediatric age. In adults, NAFLD is increasingly recognised as an independent risk factor for cardiovascular disease and also in children it has been found to be associated with cardiovascular risk factors.

At present, lifestyle intervention remains the only accepted therapy for NAFLD. Remarkably little is known about the efficacy of lifestyle interventions. Most studies are small or were performed in selected populations, often in patients treated in tertiary liver centres. Although it is considered of paramount importance to identify which lifestyle interventions are most effective, the factors associated with response to lifestyle interventions have not been studied.

The aim of this study is to determine the effect of lifestyle intervention on NAFLD in children identified by screening among those referred to a tertiary obesity centre. Moreover, we aim to identify the clinical parameters associated with response to the lifestyle intervention.

What is already known on this topic
- Non-alcoholic fatty liver disease (NAFLD) has a high prevalence among obese children.
- Lifestyle intervention is the primary therapy for NAFLD, but its efficacy has not been well determined.
- Factors related to improvement in NAFLD during treatment have not been determined.

What this study adds
- Markers of NAFLD normalise in about 60% of children who complete an intensive 6-month lifestyle intervention programme.
- Improvement in insulin sensitivity is the parameter most strongly related to improvement in NAFLD, but it explains only a small part of the observed treatment effect.
- Other factors related to successful treatment of NAFLD need to be identified so that these can be a focus for new lifestyle and drug interventions.

MATERIALS AND METHODS
Population
All children who participated in a Dutch tertiary centre-based lifestyle intervention programme...
between November 2004 and May 2008 were eligible. Inclusion criteria for this programme were severe primary obesity (body mass index adjusted for age (‘BMI-for-age’) >35 kg/m²) and primary obesity (BMI-for-age >30 kg/m²) together with obesity-related comorbidity. For participation in this study, additional exclusion criteria were (a history of) the use of steatogenic and/or antidiabetic drugs, diabetes mellitus, alcohol abuse, hepatitis B, hepatitis C or autoimmune hepatitis. The majority of children were referred by hospital-based paediatricians. The study protocol was approved by the Medical Ethics Committee of the Academic Medical Centre of the University of Amsterdam.

### Intervention

The lifestyle intervention programme consisted of scheduled exercise (three times per week for 1 h) and the promotion of self-initiated physical activities. Nutrition modification therapy was given using a non-diet approach and focused on the quality of the dietary intake and eating behaviour. Behaviour modification therapy was given and consisted of coping skills training focusing on self-regulation, self-awareness, goal setting and stimulus control. The programme was facilitated by physical education teachers, a dietician and a child psychologist. Care givers were separately educated on nutrition and behaviour modification during this programme. Children attended the sessions in an outpatient setting consisting of 12 days of treatment over a 6-month period with homework assignments or an inpatient setting consisting of 5 days of admission per week for a period of 6 months. Children were allocated to either setting based on the order of inclusion unless the treating physician judged that the patient was unfit for outpatient treatment in which case he/she was allocated to inpatient treatment.

### Measurements

Ultrasoundography of the liver, blood sampling, an oral glucose tolerance test (OGTT) and physical examination were performed at the start and at the end of 6 months of treatment. Steatosis was diagnosed based on ultrasoundography findings and scored using a scale adapted from Saverymuttu et al (Table 1). Ultrasonography was performed by a single experienced radiologist blinded to clinical data. The Philips ATL HDI 5000 ultrasound imaging platform with a 3.5 MHz transducer was used (Philips Healthcare, Eindhoven, The Netherlands). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were used as surrogate markers for steatohepatitis.

### Table 1 Scoring of liver steatosis determined by ultrasound

(adapted from Saverymuttu et al)

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (normal):</td>
<td>Normal echogenicity of liver parenchyma</td>
</tr>
<tr>
<td>1 (mild steatosis):</td>
<td>Normal visualisation of diaphragm and intrahepatic blood vessels</td>
</tr>
<tr>
<td>2 (moderate steatosis):</td>
<td>Slightly increased echogenicity of liver parenchyma</td>
</tr>
<tr>
<td>3 (severe steatosis):</td>
<td>Markedly increased echogenicity of liver parenchyma. Slightly decreased visualisation of diaphragm and intrahepatic blood vessels.</td>
</tr>
</tbody>
</table>

### Statistical analysis

Children missing end of treatment measurements were excluded from the analysis. The effect of the intervention on NAFLD was analysed using McNemar’s test for paired categorical data and \( \chi^2 \) test for independent categorical data. Changes in continuous variables were analysed using paired Student t test. Regression analyses were performed to identify factors predictive of improvement in steatosis and decrease in ALT and AST. All parameters with \( p<0.10 \) in univariate analysis were included in multivariate regression analysis (backward selection). The intraobserver variability of ultrasonography steatosis scoring was determined by repeated ultrasound in 100 patients.

### RESULTS

During the inclusion period, 180 children were treated in the lifestyle intervention programme. Eight were excluded (7 metformin use; 1 alcohol abuse). Twenty-eight children missed end of treatment measurements: 21 children dropped out during the treatment phase and 7 children did not show up at the end of treatment examinations. Those who dropped out were not significantly different for any baseline feature except for a higher prevalence of steatosis (60.7% vs 31.2%, \( p=0.002 \)) and a higher prevalence of elevated serum ALT (46.4% vs 25.5%, \( p=0.04 \)). Baseline features of the 144 children who completed treatment are shown in Table 2.

### Steatosis and serum transaminases

All biochemical and anthropometrical parameters showed significant improvement after treatment (Table 2). The mean weight reduction achieved was 12.2%. After treatment, there was a significant decrease in the prevalence of steatosis from \( n=45 \) (31.2%) to \( n=17 \) (11.9%) and the prevalence of elevated serum ALT from \( n=37 \) (25.7%) to \( n=16 \) (11.1%) and elevated serum AST from \( n=19 \) (13.3%) to \( n=6 \) (4.3%) (Figure 1). Worsening in the grade of steatosis after treatment was observed in three cases (3x1 grade). Serum liver transaminases were in the normal range in pre-treatment serum and elevated in post-treatment serum in six children. Intraobserver agreement for the ultrasonography steatosis score was observed in 57% of cases, whereas 38% showed a difference of one stage and 5% showed a difference of two stages between observations.

### Factors associated with improvement in NAFLD

Improvement in the ultrasonography determined stage of steatosis was related to a younger age, non-Caucasian ethnicity, inpatient treatment, decrease in BMI z-score, decrease in
ALT 28.2 (±12.6) 22.6 (±6.6) <0.001
AST 31.2 (±21.2) 22.8 (±12.7) <0.001
Diastolic BP (mm Hg) 80 (±11) 73 (±11) <0.001
LDL cholesterol (mmol/l) 2.46 (±0.78) 2.17 (±0.70) <0.001
HDL cholesterol (mmol/l) 1.22 (±0.29) 1.26 (±0.31) 0.01
HOMA-IR 3.4 (±1.7) 2.4 (±1.6) <0.001
Waist (cm) 105.0 (±12.6) 96.4 (±13.0) <0.001
BMI z-score 3.35 (±0.40) 2.85 (±0.56) <0.001
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; γ-GT, γ-glutamyl transpeptidase.

Table 2 Main characteristics of participants before and after 6 months of treatment (n=144)

<table>
<thead>
<tr>
<th>Degree of steatosis:</th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No steatosis (grade 0) (%)</td>
<td>68.8</td>
<td>88.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mild steatosis (grade 1) (%)</td>
<td>9.7</td>
<td>5.6</td>
<td>0.01</td>
</tr>
<tr>
<td>Moderate steatosis (grade 2) (%)</td>
<td>18.1</td>
<td>4.9</td>
<td>0.001</td>
</tr>
<tr>
<td>Severe steatosis (grade 3) (%)</td>
<td>3.5</td>
<td>1.4</td>
<td>0.001</td>
</tr>
<tr>
<td>ALT</td>
<td>28.2 (±12.6)</td>
<td>22.6 (±6.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AST</td>
<td>31.2 (±21.2)</td>
<td>22.8 (±12.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>γ-GT</td>
<td>22.4 (±9.5)</td>
<td>18.9 (±12.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Waist</td>
<td>105.0 (±12.6)</td>
<td>96.4 (±13.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>3.4 (±1.7)</td>
<td>2.4 (±1.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>1.22 (±0.29)</td>
<td>1.26 (±0.31)</td>
<td>0.01</td>
</tr>
<tr>
<td>Diastolic BP</td>
<td>80 (±11)</td>
<td>73 (±11)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic BP</td>
<td>125 (±15)</td>
<td>117 (±13)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; γ-GT, γ-glutamyl transpeptidase.

ALT, AST, and elevated aspartate aminotransferase (AST) before (white bar) and after (black bar) 6 months of treatment.

**Figure 1** Prevalence of steatosis, elevated alanine aminotransferase (ALT) and elevated aspartate aminotransferase (AST) before (white bar) and after (black bar) 6 months of treatment.

γ-glutamyl transpeptidase (γ-GT), HOMA-IR index and an increase in high-density lipoprotein cholesterol in univariate logistic regression analysis (table 3). In multivariate logistic regression analysis, only a decrease in the HOMA-IR index remained significantly associated with improvement in steatosis stage (OR 1.61, 95% CI 1.2 to 3.4).

In univariate linear regression analysis, a decrease in serum ALT was associated with male gender, inpatient treatment, decrease in BMI z-score, decrease in HOMA-IR index, decrease in waist circumference and decrease in low-density lipoprotein (LDL) cholesterol (table 4). In multivariate linear regression analysis, only a decrease in the HOMA-IR index remained significantly associated with a decrease in serum ALT; a decrease of 1 point in the HOMA-IR index resulted in a 2.6 U/l (95% CI 0.8 to 4.4) decrease in ALT.

In univariate linear regression analysis, a decrease in serum AST was associated with Arab African ethnicity, inpatient treatment, decrease in HOMA-IR index and decrease in LDL cholesterol (table 4). After combining these associated factors in a multivariate logistic regression analysis only a decrease in the HOMA-IR index remained significantly associated with a decrease in serum AST; a decrease of 1 point in the HOMA-IR index resulted in a 1.4 U/l (95% CI 0.36 to 2.46) decrease in AST.

The linear regression model for change in transaminases and HOMA-IR index had an R² value of 0.06 and 0.05 for ALT and AST, respectively. This means that a change in the HOMA-IR index only explained 5–6% of the observed changes in serum transaminases.

**DISCUSSION**

This study shows the efficacy of a 6-month lifestyle programme on NAFLD in a large unselected cohort of severely

<table>
<thead>
<tr>
<th>Table 2 Predictive factors for improvement in ultrasonography (n=144)</th>
<th>OR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male)</td>
<td>1.05 (0.30 to 3.70)</td>
<td>0.94</td>
</tr>
<tr>
<td>Age (per year)</td>
<td>0.71 (0.49 to 1.05)</td>
<td>0.09</td>
</tr>
<tr>
<td>Duration of overweight (years)</td>
<td>1.10 (0.84 to 1.44)</td>
<td>0.48</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td></td>
<td>0.07</td>
</tr>
<tr>
<td>Non-Caucasian</td>
<td></td>
<td>7.1 (0.82 to 61.0)</td>
</tr>
<tr>
<td>Puberty stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepubertal</td>
<td></td>
<td>0.22</td>
</tr>
<tr>
<td>Pubertal</td>
<td></td>
<td>1.0</td>
</tr>
<tr>
<td>Outpatient treatment</td>
<td></td>
<td>0.38 (0.08 to 1.80)</td>
</tr>
<tr>
<td>Decrease in BMI z-score (per 0.1 SD)</td>
<td></td>
<td>1.32 (1.03 to 1.70)</td>
</tr>
<tr>
<td>Decrease in waist circumference (per cm)</td>
<td></td>
<td>1.04 (0.96 to 1.12)</td>
</tr>
<tr>
<td>Decrease in HOMA-IR (per 1.0 point)</td>
<td></td>
<td>1.61 (1.07 to 2.44)</td>
</tr>
<tr>
<td>Decrease in ALT (per U/l)</td>
<td></td>
<td>1.02 (0.99 to 1.04)</td>
</tr>
<tr>
<td>Decrease in AST (per U/l)</td>
<td></td>
<td>1.07 (0.98 to 1.16)</td>
</tr>
<tr>
<td>Decrease in γ-GT (per U/l)</td>
<td></td>
<td>1.16 (0.93 to 1.36)</td>
</tr>
<tr>
<td>Increase in HDL cholesterol (per 0.1 mmol/l)</td>
<td></td>
<td>1.23 (0.96 to 1.56)</td>
</tr>
<tr>
<td>Increase in LDL cholesterol (per mmol/l)</td>
<td></td>
<td>1.38 (0.50 to 3.82)</td>
</tr>
<tr>
<td>Decrease in diastolic BP (per mm Hg)</td>
<td></td>
<td>0.97 (0.93 to 1.02)</td>
</tr>
<tr>
<td>Decrease in systolic BP (per mm Hg)</td>
<td></td>
<td>0.99 (0.96 to 1.03)</td>
</tr>
</tbody>
</table>

Those with no steatosis pre-treatment (score 0) were excluded because they could not improve their steatosis score (n=45 analysed).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; γ-GT, γ-glutamyl transpeptidase.

Values expressed as mean (±SD).

*Three stages based on Tanner stages: ‘prepubertal’ equals G/M1&P1; ‘postpubertal’ equals G/M5&P5; ‘pubertal’ equals all other Tanner stages.

*Non-Caucasian: Arab African or African; no subjects from Middle East in this group.

Those with no steatosis pre-treatment (score 0) were excluded because they could not improve their steatosis score (n=45 analysed).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; γ-GT, γ-glutamyl transpeptidase.
obese children. Steatosis, serum ALT and serum AST normalised in 62%, 57% and 68% of the participants, respectively, who completed the lifestyle programme. Furthermore, this study establishes that improvement in insulin sensitivity is the parameter most strongly associated with improvement in NAFLD achieved by lifestyle intervention.

The study population was identified by screening children referred to a tertiary obesity centre for the presence of NAFLD. This study population is therefore not comparable with other paediatric studies that recruited children referred to tertiary liver centres mostly for evaluation of elevated transaminases or children selected based on insulin resistance. Comparing paediatric studies with a similar selection of patients, we have found a similar efficacy of lifestyle intervention: normalisation of ultrasonography of exercise on peripheral and hepatic insulin sensitivity. Comparing paediatric studies with a similar selection of patients, we have found a similar efficacy of lifestyle intervention: normalisation of ultrasonography of exercise on peripheral and hepatic insulin sensitivity. Comparing paediatric studies with a similar selection of patients, we have found a similar efficacy of lifestyle intervention: normalisation of ultrasonography of exercise on peripheral and hepatic insulin sensitivity. Comparing paediatric studies with a similar selection of patients, we have found a similar efficacy of lifestyle intervention: normalisation of ultrasonography of exercise on peripheral and hepatic insulin sensitivity. Comparing paediatric studies with a similar selection of patients, we have found a similar efficacy of lifestyle intervention: normalisation of ultrasonography.

### Table 4 Prediction of a decrease in serum ALT and AST after 6 months of treatment by univariate linear regression analysis (n=144)

<table>
<thead>
<tr>
<th>Variable</th>
<th>ALT</th>
<th>p Value</th>
<th>AST</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male)</td>
<td>B = 7.9 (1.2 to 14.6)</td>
<td>0.02</td>
<td>B = 1.4 (2.6 to 5.4)</td>
<td>0.48</td>
</tr>
<tr>
<td>Age (per year)</td>
<td>B = −0.6 (−2.0 to 0.9)</td>
<td>0.44</td>
<td>B = −0.03 (−0.8 to 0.9)</td>
<td>0.39</td>
</tr>
<tr>
<td>Duration of overweight (years)</td>
<td>B = −0.1 (−1.3 to 1.2)</td>
<td>0.93</td>
<td>B = −0.1 (−0.9 to 0.7)</td>
<td>0.83</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Arab African</td>
<td>B = 7.8 (−4.7 to 20.3)</td>
<td>0.22</td>
<td>B = 7.6 (4.0 to 14.7)</td>
<td>0.04</td>
</tr>
<tr>
<td>African</td>
<td>B = −3.4 (−17.0 to 10.3)</td>
<td>0.63</td>
<td>B = −2.3 (−10.2 to 5.5)</td>
<td>0.56</td>
</tr>
<tr>
<td>Middle East</td>
<td>B = 2.0 (−6.1 to 10.1)</td>
<td>0.63</td>
<td>B = 1.5 (−3.2 to 6.2)</td>
<td>0.54</td>
</tr>
<tr>
<td>Tanner stage†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepubertal</td>
<td>Reference</td>
<td></td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Pubertal</td>
<td>B = −0.3 (−14.8 to 14.2)</td>
<td>0.97</td>
<td>B = 3.0 (−5.7 to 11.8)</td>
<td>0.61</td>
</tr>
<tr>
<td>Postpubertal</td>
<td>B = −1.2 (−16.3 to 13.9)</td>
<td>0.87</td>
<td>B = 3.4 (−5.7 to 11.8)</td>
<td>0.74</td>
</tr>
<tr>
<td>Outpatient treatment</td>
<td>B = −7.5 (−14.0 to 1.0)</td>
<td>0.02</td>
<td>B = −3.5 (−7.4 to 0.3)</td>
<td>0.07</td>
</tr>
<tr>
<td>Decrease in BMI z-score (per 0.1 SD)</td>
<td>B = 0.8 (−0.7 to 1.6)</td>
<td>0.07</td>
<td>B = 0.13 (−0.4 to 0.6)</td>
<td>0.63</td>
</tr>
<tr>
<td>Decrease in waist circumference (per cm)</td>
<td>B = 0.4 (0.1 to 0.8)</td>
<td>0.03</td>
<td>B = 0.1 (−0.1 to 0.3)</td>
<td>0.38</td>
</tr>
<tr>
<td>Decrease in HOMA-IR (per 1.0 point)</td>
<td>B = 2.6 (0.8 to 4.4)</td>
<td>0.005</td>
<td>B = 1.4 (0.4 to 2.5)</td>
<td>0.009</td>
</tr>
<tr>
<td>Increase in HDL cholesterol (per mmol/l)</td>
<td>B = −7.6 (−25.7 to 10.5)</td>
<td>0.41</td>
<td>B = 0.05 (−10.7 to 10.6)</td>
<td>0.99</td>
</tr>
<tr>
<td>Decrease in LDL cholesterol (per mmol/l)</td>
<td>B = 5.8 (0.1 to 11.5)</td>
<td>0.05</td>
<td>B = 2.9 (−0.4 to 6.2)</td>
<td>0.09</td>
</tr>
<tr>
<td>Decrease in diastolic BP (per mm Hg)</td>
<td>B = −0.1 (−0.3 to 0.2)</td>
<td>0.50</td>
<td>B = −0.05 (−0.2 to 0.1)</td>
<td>0.55</td>
</tr>
<tr>
<td>Decrease in systolic BP (per mm Hg)</td>
<td>B = 0.1 (−0.2 to 0.3)</td>
<td>0.70</td>
<td>B = 0.04 (−0.1 to 0.2)</td>
<td>0.55</td>
</tr>
</tbody>
</table>

*In case of a significant p value, a positive B value indicates a higher decrease in ALT/AST during treatment.

†Three stages based on Tanner stages: ‘prepubertal’ equals G/M1&P1; ‘postpubertal’ equals G/M5&P5; ‘pubertal’ equals all other Tanner stages.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein.
and rosiglitazone, have not been studied in children, data in adults are limited and a beneficial effect has not been well established.7 31

It should be noted, however, that the HOMA-IR index only explains 5–6% of the change in tansminases in this study. Thus, other factors not included in this study are related to the observed treatment effect. In order to identify the other factors related to the improvement in NAFLD, larger studies including more associated factors (eg, genetic) are needed.

The limitation of almost all studies on NAFLD in children, including this study, is the inaccuracy of the tools used to detect NAFLD. Ultrasonography cannot detect subtle changes in liver steatosis.32–34 Moreover, it is operator dependent, which is underscored by the modest intraobserver agreement observed in this study. Serum transaminases and γ-GT have been found to be the clinical variables correlating best with histological non-alcoholic steatohepatitis in children; however, they cannot replace histology.25 35 We assume, however, that given the relatively large sample size and longitudinal follow-up, the changes in these parameters represent changes in NAFLD. In the multivariate regression analysis, we used change in serum ALT and AST as a continuous variable, thus also including those with transaminases within the normal range at baseline. The upper limits of transaminases are arbitrary and debated, and it has been shown that transaminases within the normal range decrease in those with NAFLD in response to treatment.36 Therefore, the change in ALT and AST within the normal range in this large cohort can be considered a treatment effect on NAFLD. Notably, improvement in the HOMA-IR index was also independently correlated with improvement in γ-GT (data not shown). The use of more accurate modalities to detect steatosis and inflammation/fibrosis, such as MRI, MR proton-spectroscopy and/or histology, in future studies would possibly allow the identification of other significant biochemical or anthropometric parameters that relate to change in NAFLD.

Although patients were partially treated in an inpatient and outpatient setting, comparison of these treatments was not possible in this cohort because patients were not randomly assigned to either programme. Patients treated in an inpatient setting had a longer duration of obesity, significantly higher BMI z-score and higher waist circumference (data not shown). In multivariate regression analysis, patient setting was found to be not significantly associated with response to therapy. Including patient setting in multivariate regression analysis until the end did not alter the results.

In this study, the prevalence of steatosis and elevated ALT at baseline was higher in the 28 children who did not have endpoint measurements compared with those who had endpoint measurements. There is no theoretical basis to assume that children with steatosis and elevated ALT are more likely not to complete a lifestyle intervention programme. In two other studies describing drop out, such a difference was not observed.20 24 We therefore assume that this difference is based on coincidence.

This study shows a moderate efficacy of lifestyle intervention on NAFLD in a well-defined cohort of severely obese children. Improvement in insulin resistance is identified as the clinical parameter most strongly associated with improvement in NAFLD. Future studies should focus on identifying other factors related to successful treatment of NAFLD and exploring lifestyle and drug interventions based on these factors.

**Funding** The lifestyle intervention programme of the Childhood Obesity Clinic Heideheuvel is supported financially by the Dutch Ministry of Health, Welfare and Sport.

**Competing interests** None.

**Contributors** All authors contributed equally to this study.

**Ethics approval** This study was conducted with the approval of the Medical Ethics Committee of the Academic Medical Centre of the University of Amsterdam.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**


Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement


Arch Dis Child 2011 96: 669-674 originally published online April 25, 2011
doi: 10.1136/adc.2010.199760

Updated information and services can be found at:
http://adc.bmj.com/content/96/7/669.full.html

These include:

References
This article cites 35 articles, 7 of which can be accessed free at:
http://adc.bmj.com/content/96/7/669.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Liver disease (96 articles)
- Child health (2013 articles)
- Health education (324 articles)
- Health promotion (360 articles)
- Obesity (nutrition) (178 articles)
- Obesity (public health) (178 articles)
- Clinical diagnostic tests (526 articles)
- Diet (200 articles)
- Epidemiologic studies (919 articles)
- Radiology (451 articles)
- Radiology (diagnostics) (355 articles)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/